# AIsphere Completes 2.98 Billion Yuan Series C Financing

- Category: Flash (快讯)
- Published: 2026-07-14T12:00:00.000Z
- Source date: 2026-07-14
- HTML: https://www.88z.ai/en/news/flash-20260714-04b5a8b2ad20daae
- Markdown: https://www.88z.ai/en/news/flash-20260714-04b5a8b2ad20daae.md
- Other language: https://www.88z.ai/news/flash-20260714-04b5a8b2ad20daae.md

AIsphere announced the completion of its overall Series C financing, totaling 2.98 billion yuan. The Series C+ round was led by Alibaba, with participation from over ten domestic and international institutions. Funds will be used for R&D of video generation foundation models and real-time world models, as well as global product growth. Its PixVerse platform has over 150 million global users. Earlier this year, it launched PixVerse R1, the world's first general real-time world model supporting 10

## At a glance

- AIsphere completes 2.98 billion yuan Series C financing, led by Alibaba in C+ round
- Funds allocated for model R&D and global expansion; PixVerse exceeds 150 million users

## The update

AIsphere officially announced the completion of its overall Series C financing, with a total amount of 2.98 billion yuan. The Series C+ round was led by Alibaba and saw participation from more than ten domestic and international institutions. The raised funds will be primarily directed toward the research and development of video generation foundation models and real-time world models, while also supporting the global growth of its products. Currently, the company's PixVerse platform has surpassed 150 million users worldwide. Earlier this year, AIsphere launched PixVerse R1, the world's first general real-time world model supporting 1080P resolution. Additionally, the company has established strategic partnerships with industry players such as Mango Media and Alibaba to jointly promote industry development.

## Sources

- [爱诗科技 AIsphere](https://mp.weixin.qq.com/s/mWK96cTdJfCcw-N1U0AMpw) (2026-07-14)

This article is an AI-assisted synthesis by 88Z AI based on the public sources below. Product claims and availability are attributed to their publishers. It does not represent independent testing or first-hand reporting.